Searching for smart, safe news you can TRUST?

Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Searching for smart, safe news you can TRUST?

Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

One vial of the drug Remdesivir lies on a table. Photo: Ulrich Perrey/AFP via Getty Images

A World Health Organization panel of experts on Thursday recommended against the use of Gilead Sciences' remdesivir as a COVID-19 treatment.

Why it matters: The recommendation breaks with the U.S. Food and Drug Administration, which approved the antiviral drug as a COVID-19 treatment in October.

What they're saying: The WHO panel "concluded that remdesivir has no meaningful effect on mortality or on other important outcomes for patients, such as the need for mechanical ventilation or time to clinical improvement," the experts said in a news release, per the New York Times.

  • The experts, who published their guidance in the the journal the BMJ, said they "concluded that the evidence did not prove that remdesivir has no benefit; rather, there is no evidence based on currently available data that it does improve patient-important outcomes."
  • "Especially given the costs and resource implications associated with remdesivir, but consistent with the approach that should be taken with any new drug, the panel felt the responsibility should be on demonstrating evidence of efficacy, which is not established by the currently available data."
  • The panel reviewed data from four randomized trials.

Gilead Sciences said in a statement: “We are disappointed the WHO guidelines appear to ignore this evidence at a time when cases are dramatically increasing around the world and doctors are relying on Veklury as the first and only approved antiviral treatment for patients with Covid-19 in approximately 50 countries," per the WSJ. Veklury is the trade name for remdesivir.

Go deeper

California governor and family in quarantine after coronavirus exposure

California Gov. Gavin Newsom. Photo: Justin Sullivan/Getty Images

California Gov. Gavin Newsom (D) tweeted late Sunday that he and his family are quarantining after being exposed to COVID-19.

Details: Newsom said they learned Friday that three of his children had come into contact with a California Highway Patrol officer who tested positive for the coronavirus. "Thankfully, the entire family tested negative today," Newsom said.

Operation Warp Speed leader: COVID vaccine push is "isolated from a political environment"

Moncef Slaoui in the Rose Garden on Nov. 13. Photo: Mandel Ngan/AFP via Getty Images

Moncef Slaoui, the White House's top scientific adviser to Operation Warp Speed, told Chuck Todd on "Meet the Press" on Sunday that the Trump administration's efforts to accelerate the development of a coronavirus vaccine is "isolated from a political environment" and that a change in administration "doesn't, frankly, make a difference" on its efficacy.

Why it matters: Slaoui told ABC's George Stephanopoulos on Sunday that he has not yet had contact with Joe Biden's transition team, as the president-elect prepares to inherit one of the country's biggest crises ahead of an expected vaccine distribution effort that would require massive logistical cooperation between states and the federal government.

In photos: Americans wait at food banks before Thanksgiving

Residents line up in their cars at a food distribution site in Clermont, Fla., Nov. 21. Photo: Paul Hennessy/SOPA Images/LightRocket via Getty Images

Thousands of Americans waited in long lines at food banks in the week before Thanksgiving to pick up turkeys, canned goods, broccoli and other vegetables.

Why it matters: As the holiday season approaches, families across the U.S. are in need of food assistance due to chronic unemployment and economic hardship caused by COVID-19 — and many food pantries already served an unprecedented number of people this spring.